Recognizing and Managing Adverse Events in Y-90 Radioembolization

Overview

Journal Semin Intervent Radiol

Specialty Radiology

Date 2021 Oct 11

PMID 34629713

Citations 3

Authors

Grace L Laidlaw

Guy E Johnson

Affiliations

Soon will be listed here.

Abstract

Transarterial radioembolization using yttrium-90 (Y-90) microspheres is an important therapy in the management of unresectable primary liver tumors or hepatic metastases. While radioembolization is generally well-tolerated, it is not free from adverse events, and familiarity with the prevention and treatment of radioembolization-specific complications is an important component of patient care. This article aims to review radioembolization-specific toxicities stratified by hepatic, extrahepatic, and systemic effects, with a focus on preventing and mitigating radioembolization-induced morbidity.

Citing Articles

Ablation versus Radiation Segmentectomy for Small Liver Tumors.

Ozen M, Patel R Semin Intervent Radiol. 2024; 40(6):511-514.

PMID: 38274221 PMC: 10807957. DOI: 10.1055/s-0043-1777714.

Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series.

Vermeulen S, De Keukeleire K, Dorny N, Colle I, Van den Bossche B, Nuttens V Cancers (Basel). 2023; 15(19).

PMID: 37835485 PMC: 10571855. DOI: 10.3390/cancers15194791.

Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review.

Shah H, Ruppell E, Bokhari R, Aland P, Lele V, Ge C Eur J Radiol Open. 2023; 10:100477.

PMID: 36785643 PMC: 9918751. DOI: 10.1016/j.ejro.2023.100477.

References

Kallini J, Gabr A, Thorlund K, Balijepalli C, Ayres D, Kanters S . Comparison of the Adverse Event Profile of TheraSphere with SIR-Spheres for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. Cardiovasc Intervent Radiol. 2017; 40(7):1033-1043. DOI: 10.1007/s00270-017-1594-4. View

Dezarn W, Cessna J, DeWerd L, Feng W, Gates V, Halama J . Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011; 38(8):4824-45. DOI: 10.1118/1.3608909. View

Thuring J, Zimmermann M, Bruners P, Pedersoli F, Schulze-Hagen M, Barzakova E . Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment. Cardiovasc Intervent Radiol. 2019; 42(10):1494-1499. PMC: 6715807. DOI: 10.1007/s00270-019-02294-7. View

Padia S, Lewandowski R, Johnson G, Sze D, Ward T, Gaba R . Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. J Vasc Interv Radiol. 2016; 28(1):1-15. DOI: 10.1016/j.jvir.2016.09.024. View

Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N . Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2018; 29(11):1502-1510.e1. DOI: 10.1016/j.jvir.2018.06.027. View

Salem R, Parikh P, Atassi B, Lewandowski R, Ryu R, Sato K . Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008; 31(5):431-8. DOI: 10.1097/COC.0b013e318168ef65. View

Murthy R, Brown D, Salem R, Meranze S, Coldwell D, Krishnan S . Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007; 18(4):553-61. DOI: 10.1016/j.jvir.2007.02.002. View

Su Y, Mackey R, Riaz A, Gates V, Benson 3rd A, Miller F . Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. J Vasc Interv Radiol. 2017; 28(11):1520-1526. DOI: 10.1016/j.jvir.2017.05.011. View

Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T . Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021; 94(1119):20200752. PMC: 8011251. DOI: 10.1259/bjr.20200752. View

10.

Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R . Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013; 11(10):1358-1365.e1. DOI: 10.1016/j.cgh.2013.04.028. View

11.

Devulapalli K, Fidelman N, Soulen M, Miller M, Johnson M, Addo E . Y Radioembolization for Hepatic Malignancy in Patients with Previous Biliary Intervention: Multicenter Analysis of Hepatobiliary Infections. Radiology. 2018; 288(3):774-781. DOI: 10.1148/radiol.2018170962. View

12.

Gates V, Hickey R, Marshall K, Williams M, Salzig K, Lewandowski R . Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. Eur J Nucl Med Mol Imaging. 2015; 42(13):2038-44. DOI: 10.1007/s00259-015-3122-6. View

13.

Alexander E, Pantel A, Carlin S, Beckmann N, Mick R, Pryma D . Prospective Study of Systemic Yttrium-90 Elution during Radioembolization of Hepatic Metastases. J Vasc Interv Radiol. 2020; 31(12):2007-2013.e1. DOI: 10.1016/j.jvir.2020.08.011. View

14.

Collins J, Salem R . Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Intervent Radiol. 2012; 28(2):240-5. PMC: 3193333. DOI: 10.1055/s-0031-1280673. View

15.

Bester L, Meteling B, Pocock N, Pavlakis N, Chua T, Saxena A . Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2011; 23(1):96-105. DOI: 10.1016/j.jvir.2011.09.028. View

16.

Zhang Y, Li Y, Ji H, Zhao X, Lu H . Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. Biosci Trends. 2015; 9(5):289-98. DOI: 10.5582/bst.2015.01089. View

17.

Currie B, Hoteit M, Ben-Josef E, Nadolski G, Soulen M . Radioembolization-Induced Chronic Hepatotoxicity: A Single-Center Cohort Analysis. J Vasc Interv Radiol. 2019; 30(12):1915-1923. DOI: 10.1016/j.jvir.2019.06.003. View

18.

Chow P, Gandhi M, Tan S, Khin M, Khasbazar A, Ong J . SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018; 36(19):1913-1921. DOI: 10.1200/JCO.2017.76.0892. View

19.

Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck K, Schenning R, Kaufman J . Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol. 2018; 29(6):858-865. DOI: 10.1016/j.jvir.2018.02.002. View

20.

Salem R, Johnson G, Kim E, Riaz A, Bishay V, Boucher E . Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021; 74(5):2342-2352. PMC: 8596669. DOI: 10.1002/hep.31819. View